TY - JOUR KW - AIDS Vaccines KW - Acquired Immunodeficiency Syndrome KW - Animals KW - Antibodies, Viral KW - Cytopathogenic Effect, Viral KW - Drug Design KW - HIV KW - HIV Infections KW - Humans KW - Immune System KW - Immunocompetence KW - Immunologic Memory KW - Immunotherapy, Adoptive KW - Lymphocytic Choriomeningitis KW - Lymphocytic choriomeningitis virus KW - Mice KW - T-Lymphocyte Subsets KW - Viral Vaccines KW - Virus Latency AU - Zinkernagel R AB -

Immunity and immunopathology of HIV infections leading to AIDS are reviewed from an evolutionary point of view. Accordingly infectious agents and host defences have co-evolved to reach balanced states where virus and host survive. While HIV has not quite yet reached an optimal balance, tuberculosis (TB), leprosy, HBV, HCV in humans or lymphocytic choriomeningitis virus (LCMV) in mice have successfully established persistence. These non- or poorly-cytopathic infections infect the next host usually before or at birth while hosts are immunoincompetent. They also infect immunocompetent hosts to persist at low levels concomitant with an ongoing T and B cell immune response that is repeatedly triggered by latent or persistent infection of extralymphatic or lymphatic host cells. This infectious or infection-immunity is the basis for cellular immunoprotection by antigen activated T cells. Because we cannot imitate this infection-immunity long-term and cannot build polyspecific vaccine combinations covering all possible neutralising variants yet, vaccines against TB, leprosy, HCV and HIV only protect transiently and incompletely.

BT - Vaccine C1 - http://www.ncbi.nlm.nih.gov/pubmed/11983244?dopt=Abstract DA - 2002 May 06 DO - 10.1016/s0264-410x(02)00066-x IS - 15 J2 - Vaccine LA - eng N2 -

Immunity and immunopathology of HIV infections leading to AIDS are reviewed from an evolutionary point of view. Accordingly infectious agents and host defences have co-evolved to reach balanced states where virus and host survive. While HIV has not quite yet reached an optimal balance, tuberculosis (TB), leprosy, HBV, HCV in humans or lymphocytic choriomeningitis virus (LCMV) in mice have successfully established persistence. These non- or poorly-cytopathic infections infect the next host usually before or at birth while hosts are immunoincompetent. They also infect immunocompetent hosts to persist at low levels concomitant with an ongoing T and B cell immune response that is repeatedly triggered by latent or persistent infection of extralymphatic or lymphatic host cells. This infectious or infection-immunity is the basis for cellular immunoprotection by antigen activated T cells. Because we cannot imitate this infection-immunity long-term and cannot build polyspecific vaccine combinations covering all possible neutralising variants yet, vaccines against TB, leprosy, HCV and HIV only protect transiently and incompletely.

PY - 2002 SP - 1913 EP - 7 T2 - Vaccine TI - Immunity, immunopathology and vaccines against HIV? VL - 20 SN - 0264-410X ER -